Cholera enterotoxin (CT) is produced by Vibro cholerae and excreted into the culture medium as an extracellular protein. CT consists of one A polypeptide and five B polypeptides associated by noncovalent bonds, and CT-B interacts with CT-A primarily via the A2 domain. Treatment of CT with trypsin cleaves CT-A into Al and A2 fragments that are linked by a disulfide bond. CT-B binds to ganglioside GM,, which functions as the plasma membrane receptor for CT, and the enzymatic activity of Al causes the toxic effects of CT on target cells. We constructed translational fusions that joined foreign proteins via their carboxyl termini to the A2 domain of CT-A, and we studied the interactions of the fusion proteins with CT-B. The A2 domain was necessary and sufficient to enable bacterial alkaline phosphatase (BAP), maltose-binding protein (MBP) or 1-lactamase (BIA) to associate with CT-B to form stable, immunoreactive, holotoxin-like chimeras. Each holotoxin-like chimera was able to bind to ganglioside GM,. Holotoxin-like chimeras containing the BAP-A2 and BLA-A2 fusion proteins had BAP activity and BLA activity, respectively. We constructed BAP-A2 mutants with altered carboxyl-terminal sequences and tested their ability to assemble into holotoxin-like chimeras. Although the carboxyl-terminal QDEL sequence of the BAP-A2 fusion protein was not required for interaction with CT-B, most BAP-A2 mutants with altered carboxyl termini did not form holotoxin-like chimeras. When holotoxin-like chimeras containing BAP-A2, MBP-A2, or BLA-A2 were synthesized in V. cholerae, they were found predominantly in the periplasm. The toxin secretory apparatus of V. cholerae was not able, therefore, to translocate these holotoxin-like chimeras across the outer membrane.
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JOBLING AND HOLMES [14] ). Bacteria were grown in 2YT liquid medium (24) in Erlenmeyer flasks at 37°C with shaking (200 rpm) or plated on LB agar plates (21) with antibiotics as indicated for specific experiments (ampicillin, 50 ,ug/ml; kanamycin, 25 ,ug/ml; tetracycline, 10 ,ug/ml).
Plasmids used in this study are described in Table 1 (12) and are shown together with the corresponding amino acid translations in Table 2 . Fig. 1A ) to create pMGJ96 was constructed by cloning in a SmaI-HindIII fragment from pMGJ6730 into StuIHindIII-cut pMal-p. The SmaI site of pMGJ6730 was introduced by oligonucleotide-directed mutagenesis, silently mutating the codons for residues 185 and 186 (CCGGGT CCCGGG, Pro-Gly). The fusion protein MBP-A2186-240 encoded by pMGJ96 retains the complete cystine loop present between CT-Al and CT-A2 ( Table 2) .
Construction of BLA fusions to CT-A2 domain. To enable mutation of the bla gene (in the phagemid vector pSKII-) without selection for ampicillin resistance (Ap%, we cloned in a kanamycin resistance (Kmr) gene to provide an alternative means of selection. The Kmr gene from pK18 was cloned as an NheI-BstBI fragment into pSKII-cut with XbaI and AccI to create pMGJ99 (Apr Kmr, Fig. 1B) . The single-stranded (ss) origin of replication enabled mutagenesis to be performed on ssDNA rescued by R408 helper bacteriophage as previously described (12) . The His-Trp residues encoded at the carboxyl terminus of the vector-derived bla gene were mutated to Asp-Ile, creating an EcoRV site, with the oligonucleotide 5' CTGATTAAGGATATCTAACTGT CAG 3'. A clone (pMGJ9901) containing an EcoRV site was obtained with the desired mutation. The mutated bla gene was subcloned as an EcoRV-SspI fragment into the SmaI site of pK18, creating pMGJ102, which expressed a BLA fusion to the LacZcL peptide. A BLA-A2 hybrid holotoxincontaining clone (pMGJ104) was constructed by inserting a ClaI-HindIII fragment from pMGJ64 (cixA ctxB+) containing the CT-A2-encoding domain and the ctxB gene into AccI-HindIII-cut pMGJ102, such that the bla and CT-A2-coding sequences were joined by a five-codon linker derived from the multiple cloning site (Table 2) , creating the fusion polypeptide BLA'-A2193240. To mutate the sequence coding for the Asp-Gly residues back to wild type (with respect to BLA, His-Trp), we transferred the insert from pMGJ104 to the vector pUK21 (Kmr, possessing an ss origin) to create pMGJ110. This clone was mutated with the oligonucleotide 5' AGAGGACCCCAATGCIlrAATCA 3' to create pMGJ111, such that the amino acid translation of the resulting fusion joint was HWGLES ( Table 2 ). The vector pUK21 has a mutated lac promoter which lowers activity to 10% of normal (34) . We found this promoter to be only weakly active in V. cholerae, and consequently for highlevel expression in V. cholerae, the insert from pMGJ111 was transferred to pK18 (a vector with a normal lac promoter) as a HindIII-KpnI fragment, creating pMGJ112.
Detection of holotoxin-like chimeras. Holotoxin-like chimeras containing CT-A2 fusion proteins were detected and quantified with the modified ganglioside GMl-solid-phase radioimmunoassay (GM1-SPRIA) (12), using polyclonal rabbit antisera against BAP, MBP, or BLA as appropriate for Rabbit anti-BAP and rabbit anti-BLA antisera were purchased from 5Prime-3Prime (Boulder, Colo.), rabbit anti-MBP was from New England Biolabs (Beverly, Mass.), and rabbit anti-CTB 10 was prepared in our laboratory.
RESULTS
Characterization of BAP-A2 fusion protein.
To determine whether the CT-A2 domain was able to confer on an unrelated protein the ability to associate with CT-B, we made a construct (pMGJ83) expressing both CT-B and a hybrid polypeptide consisting of BAP fused at its carboxyl terminus to CT-A2 (BAP-A2). The predicted mass of the mature BAP-A2 fusion protein is 52 kDa, compared with 27 kDa for CT-A. Assays of crude periplasmic extracts from E. coli CC118(pMGJ83) by GMl-SPRIA (Fig. 2) demonstrated that immunoreactive alkaline phosphatase bound to the ganglioside-coated plates. In striking contrast, the BAP-A2 fusion protein produced by the related construct pMGJ83-1, which has a frameshift mutation in citB and does not make CT-B, failed to react in the GMl-SPRIA. Detection of immunoreactive alkaline phosphatase by GMl-SPRIA was dependent, therefore, on interaction of the fusion protein with CT-B to form a holotoxin-like chimera. Extracts of CC118(pMGJ83) and CC118(pMGJ83-1) both contained high levels of alkaline phosphatase activity (data not shown). The holotoxin-like chimeras also had alkaline phosphatase activity detectable ( Table 2 ). When syntheses of BAP-A2222-240 and CT-B were induced from TX1(pMJG98), CT-B and active alkaline phosphatase were both secreted to the periplasm, but no holotoxin-like chimeras containing the fusion polypeptide were detected by GMl-SPRIA (data not shown). Next, we constructed additional variants of BAP-A2 to analyze the role of the carboxyl terminus of the A2 domain in assembly of holotoxin-like chimeras (Table 3 ). The parental plasmid for these constructs was pMGJ83, which contains an EcoRI site at the 3' end of ctxA, resulting in a change of the carboxyl-terminal sequence of the A2 domain from KDEL in wild type to QDEL in pMGJ83. Control experiments demonstrated that introduction of the QDEL sequence into CT had no apparent effect on holotoxin assembly or toxicity (data not shown). Because the plasmids that expressed these modified BAP-A2 polypeptides did not encode cixB, the ability of the modified BAP-A2 fusion proteins to form holotoxin-like chimeras was tested by complementation in E. coli with CT-B expressed from pMGJ85. All the mutants made active alkaline phosphatase, and the range of alkaline phosphatase activity in extracts containing the various mutants was approximately threefold (data not shown). The initial constructs pMGJ84 and pMGJ84-1 produced BAP-A2 fusion proteins with carboxylterminal extensions of 75 and 15 amino acids, respectively, and both were greatly impaired in their ability to form holotoxin-like chimeras (Fig. 4) . Plasmids pMGJ84-2 through pMGJ84-10 were derived from pMGJ84-1 and encoded additional changes at the carboxyl terminus of the A2 domain. The mutant fusion protein encoded by pMGJ84-9 had RGGAR substituted for QDEL and formed holotoxinlike chimeras in amounts comparable to BAP-A2 from pMGJ83-1 (Fig. 4) . Constructs that encoded mutant proteins with substitutions starting before the QDEL sequence (pMGJ84-3, -8, and -10) failed to assemble into holotoxinlike chimeras, and the mutants with QDEL replaced with sequences other than RGGAR that varied in length from 4 to 16 residues yielded only small amounts of immunoreactive holotoxin-like chimeras. Effects of ctxB mutations on formation of holotoxin-like chimeras. Previous studies showed that mutant CT-B containing a negatively charged amino acid substituted for Arg-35 was unable to associate with native CT-A to form stable holotoxin (12) . We tested several mutant CT-B polypeptides for their ability to associate with BAP-A2 in E. coli to form holotoxin-like chimeras (Fig. 5) . Mutant CT-B polypeptides with Glu-35 or Asp-35 did not form holotoxinlike chimeras, but mutant CT-B polypeptides with Asn-35 or Asp-34 did. All these strains produced high levels of immunoreactive CT-B and BAP-A2 protein with alkaline phosphatase activity (data not shown). These observations indicate that residue 35 of CT-B is directly involved in, or is important for, the association of CT-B with the A2 domain of BAP-A2 in holotoxin-like chimeras.
Inability of V. chokrae to excrete holotoxin-like chimeras containing BAP-A2, MBP-A2, or BLA-A2. We expressed the BAP-A2, MBP-A2, and BLA-A2 hybrid toxin operons in V. cholerae CVD44, a strain deleted for the clx operon, and examined the formation and localization of the holotoxinlike chimeras (Fig. 6) . Because BLA-A2 was poorly expressed from the altered lac promoter of pMGJ111 in V. cholerae, we constructed pMGJ112 (Fig. 1B) , in which BLA-A2 is expressed from the lac promoter of pK18, and used it for these experiments. In V. cholerae CVD44, the holotoxin-like chimeras were all localized predominantly in the periplasm and were not excreted into the culture medium. In contrast, pentameric CT-B produced simultaneously with the hybrid toxins in CVD44 was excreted into the culture medium. These results demonstrated that the toxin secretory apparatus in V. cholerae CVD44 was functional but unable to translocate the holotoxin-like chimeras across the outer membrane. The failure of the holotoxin-like chimeras to be excreted by V. cholerae was most likely determined, therefore, by the characteristics of their constituent BAP-A2, MBP-A2, and BLA-A2 hybrid polypeptides. chimeras. Our findings establish that the A2 domain is sufficient to enable hybrid proteins, and presumably also CT-A, to interact with CT-B during assembly. Duffy et al. (2) proposed that the amino terminus of Al participates in binding of CT-A to CT-B. The possibility that the Al domain may contribute to the assembly process for native CT is not excluded by our findings.
The crystal structure of CT is not yet published, but the conformation of CT is reported (5) to be almost identical to that of the related protein LTp from E. coli (32) . The crystal structure of LTp showed that A2 contains an a-helix (residues 200 to 222) that interacts extensively with Al and an extended chain (residues 222 to 228) which projects into the core of the LT-B pentamer and interacts with each of the LT-B polypeptides (31, 32 Among the BAP-A2 mutants with altered carboxyl termini, only those with QDEL (present in the parental construct used in this study) or RGGAR substituted for the C-terminal KDEL sequence of wild-type CT-A formed normal amounts of stable holotoxin-like chimeras with CT-B. These findings demonstrated that the sequence at the carboxyl-terminal end of A2 has significant effects on the assembly or stability of holotoxin-like chimeras, even though the wild-type KDEL sequence is not essential. Removal or substitution of nine or more residues at the carboxyl-terminal end of A2 resulted in complete loss of ability of BAP-A2 fusion proteins to assemble into holotoxin-like chimeras. Our BAP-A2 fusion proteins that were not truncated at the carboxyl-terminal end of A2 but were deficient in forming holotoxin-like chimeras had at least one hydrophobic (I or L) or bulky (Y) residue substituted for D or E in the KDEL sequence, and such substitutions may prevent the normal interaction of A2 with CT-B. In the original report on the three-dimensional structure of LTp, the positions of the last eight residues (233 to 240) of the A2 domain were not well resolved (32) . Analysis of crystals containing LTp with galactose, and higher-resolution analysis of LTp alone, demonstrated that the carboxyl terminus of A2 extends out through the core of the B pentamer and includes a short, one-and-one-half-turn a-helix in the previously unresolved region (31) . This structure suggests that mutants or fusion proteins with extensions from the carboxyl terminus of A2 should not necessarily be incapable of assembling into stable holotoxins. Indeed, a fusion of E. coli heat-stable enterotoxin to the carboxyl-terminal end of LT-A via a synthetic linker peptide was reported to assemble with LT-B into a holotoxin-like chimera (25, 27) .
Our previous finding that mutant CT-B proteins with negatively charged residues substituted for Arg-35 were unable to form holotoxin with CT-A led us to consider the possibility that there might be a charge-charge repulsion between the CT-B mutants and CT-A (12). However, the three-dimensional structure of the related LTp holotoxin does not show any interaction of CT-B Arg-35 with the A2 domain, but Arg-35 does form a salt bridge with Glu-11 of the neighboring B polypeptide (30) . If the same interaction occurs between the conserved Arg-35 and Glu-11 residues in CT-B, the Asp-35 and Glu-35 mutations could disrupt this salt bridge and cause a conformational change in the B pentamer that might prevent assembly or reduce stability of the holotoxin, while still permitting pentamerization, GMlbinding activity, and immunoreactivity of the mutant CT-B polypeptides. Additional studies will be needed to define the effects of these mutations on the tertiary structure of the mutant CT-Bs.
Assembly of holotoxin-like chimeras required concurrent synthesis and secretion of the BAP-A2 fusion protein and CT-B, since addition of BAP-A2 to extracts containing pentameric CT-B did not result in formation of holotoxinlike chimeras. This is consistent with the hypothesis that CT-A acts as a nidus for interaction with CT-B during formation of holotoxin (7) . The recent crystallographic studies of LTp, indicating that the extended-chain region of A2 passes through the narrow core of the B pentamer and is flanked by a-helical regions of A2, are also consistent with the proposal that B pentamer assembles in vivo around the extended-chain region of A2. Our studies did not address quantitatively the kinetics of assembly of BAP-A2, MBP-A2, or BLA-A2 with Cr-B, but substantial amounts of holotoxin-like chimeras were formed with each of these hybrid proteins.
The secretion apparatus of V. cholerae recognizes and exports to the culture medium native CT and E. coli LT (22) and holotoxin-like chimeras containing some but not all fusions of small polypeptides to CT-B (26) or LT (29) . However, none of the holotoxin-like chimeras that we constructed in this study was excreted as an extracellular protein by V. cholerae. BAP (47-kDa monomer) and MBP (41 kDa) are much larger and BLA (29 kDa) is slightly larger than the Al domain of CT-A (22 kDa). The holotoxin-like chimeras that we studied had predicted masses of 109 kDa for BAP-A2, 104 kDa for MBP-A2, and 92 kDa for BLA-A2, compared with 84 kDa for native CT. The holotoxin-like chimera containing BAP-A2 probably also dimerized via its BAP domain, as suggested by the alkaline phosphatase activity of the holotoxin-like chimera (28) . Failure of V.
cholerae to excrete the holotoxin-like chimeras could reflect steric hindrance within the toxin secretory apparatus, either because the holotoxin-like chimeras are larger than CT or because the conformations of the hybrid polypeptides are substantially different from that of CT-A. The crystallographic studies of LTp showed extensive interaction between Al and the long a-helical region of A2 in LT-A. Similar interactions of the A2 region will probably not occur with the BAP, MBP, and BLA portions of the A2 hybrid polypeptides, and it is possible that the holotoxin-like chimeras containing BAP-A2, MBP-A2, and BLA-A2 are less compact than native CT. Because CT-B and LT-B can be excreted as pentameric B subunits into the culture medium by strains of V. cholerae that do not make the corresponding A polypeptides, but CT-A or LT-A cannot be translocated across the outer membrane of V. cholerae unless the corresponding B subunits are present, recognition of CT or LT by the toxin secretory apparatus is believed to be specific for the enterotoxin B subunits (8) .
In conclusion, we constructed several fusion proteins consisting of BAP, MBP, or BLA linked at their carboxyl termini to the A2 domain of CT. The A2 domain of the fusion proteins renders them competent to associate with CT-B to form holotoxin-like chimeras. The structures of the A2 domain of the fusion proteins and of CT-B were modified in several ways by protein engineering to provide tools for analyzing the molecular basis for assembly of CT. We expect that the model described, based on analysis of holotoxin-like chimeras, will be useful for future studies of the toxin secretory apparatus of V. cholerae and for the development of hybrid neoantigens for use in studies of immunity to cholera and other microbial diseases. 
